44 research outputs found
Hypomorphic FANCA mutations correlate with mild mitochondrial and clinical phenotype in Fanconi anemia
Fanconi anemia is a rare disease characterized by congenital malformations, aplastic anemia, and predisposition to cancer. Despite the consolidated role of the Fanconi anemia proteins in DNA repair, their involvement in mitochondrial function is emerging. The purpose of this work was to assess whether the mitochondrial phenotype, independent of genomic integrity, could correlate with patient phenotype. We evaluated mitochondrial and clinical features of 11 affected individuals homozygous or compound heterozygous for p.His913Pro and p.Arg951Gln/Trp, the two residues of FANCA that are more frequently affected in our cohort of patients. Although p.His913Pro and p.Arg951Gln proteins are stably expressed in cytoplasm, they are unable to migrate in the nucleus, preventing cells from repairing DNA. In these cells, the electron transfer between respiring complex I-III is reduced and the ATP/AMP ratio is impaired with defective ATP production and AMP accumulation. These activities are intermediate between those observed in wild-type and FANCA-/- cells, suggesting that the variants at residues His913 and Arg951 are hypomorphic mutations. Consistent with these findings, the clinical phenotype of most of the patients carrying these mutations is mild. These data further support the recent finding that the Fanconi anemia proteins play a role in mitochondria, and open up possibilities for genotype/phenotype studies based on novel mitochondrial criteria
An Exploratory Study of Field Failures
Field failures, that is, failures caused by faults that escape the testing
phase leading to failures in the field, are unavoidable. Improving verification
and validation activities before deployment can identify and timely remove many
but not all faults, and users may still experience a number of annoying
problems while using their software systems. This paper investigates the nature
of field failures, to understand to what extent further improving in-house
verification and validation activities can reduce the number of failures in the
field, and frames the need of new approaches that operate in the field. We
report the results of the analysis of the bug reports of five applications
belonging to three different ecosystems, propose a taxonomy of field failures,
and discuss the reasons why failures belonging to the identified classes cannot
be detected at design time but shall be addressed at runtime. We observe that
many faults (70%) are intrinsically hard to detect at design-time
Recommended from our members
Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients.
OBJECTIVE: The efficacy of rituximab (RTX) in systemic lupus erythematosus (SLE) is a subject of debate. This study was undertaken to investigate the outcomes of RTX treatment in a European SLE cohort, with an emphasis on the role of RTX as a maintenance agent. METHODS: All patients with SLE who were receiving RTX as induction therapy in 4 centers were included. Patients who received a single course of RTX and those who received RTX maintenance treatment (RMT) were followed up after treatment. Disease flares during the follow-up period were defined as an increase in disease activity and the number or dose of immunosuppressive drugs. RESULTS: Of 147 patients, 27% experienced treatment failure at 6 months. In a multivariate analysis, a low number of previous immunosuppressive therapies (P = 0.034) and low C4 levels (P = 0.008) reduced the risk of treatment failure. Eighty patients received RMT over a median of 24.5 months during which 85 relapses, mainly musculoskeletal, were recorded (1.06 per patient). At the time of the last RTX course, 84% of the patients were in remission. Twenty-eight (35%) of 80 patients never experienced a flare during RMT and had low damage accrual. Active articular disease at the time of the first RTX administration was associated with a risk of flare during RMT (P = 0.011). After RMT, relapse-free survival was similar to that in patients receiving a single RTX course (P = 0.72). CONCLUSION: RMT is a potential treatment option for patients with difficult-to-treat disease. Relapses occur during RMT and are more likely in those with active articular disease at the time of the first RTX administration. Relapse risk after RMT remains high and apparently comparable to that seen after a single RTX course
Molecular analysis of Fanconi anemia: the experience of the Bone Marrow Failure Study Group of the Italian Association of Pediatric Onco-Hematology
Fanconi anemia is an inherited disease characterized by congenital malformations, pancytopenia, cancer predisposition, and sensitivity to cross-linking agents. The molecular diagnosis of Fanconi anemia is relatively complex for several aspects including genetic heterogeneity with mutations in at least 16 different genes. In this paper, we report the mutations identified in 100 unrelated probands enrolled into the National Network of the Italian Association of Pediatric Hematoly and Oncology. In approximately half of these cases, mutational screening was carried out after retroviral complementation analyses or protein analysis. In the other half, the analysis was performed on the most frequently mutated genes or using a next generation sequencing approach. We identified 108 distinct variants of the FANCA, FANCG, FANCC, FANCD2, and FANCB genes in 85, 9, 3, 2, and 1 families, respectively. Despite the relatively high number of private mutations, 45 of which are novel Fanconi anemia alleles, 26% of the FANCA alleles are due to 5 distinct mutations. Most of the mutations are large genomic deletions and nonsense or frameshift mutations, although we identified a series of missense mutations, whose pathogenetic role was not always certain. The molecular diagnosis of Fanconi anemia is still a tiered procedure that requires identifying candidate genes to avoid useless sequencing. Introduction of next generation sequencing strategies will greatly improve the diagnostic process, allowing a rapid analysis of all the genes
The Clinical Impact of Methotrexate-Induced Stroke-Like Neurotoxicity in Paediatric Departments: An Italian Multi-Centre Case-Series
IntroductionStroke-like syndrome (SLS) is a rare subacute neurological complication of intrathecal or high-dose (>= 500 mg) Methotrexate (MTX) administration. Its clinical features, evoking acute cerebral ischaemia with fluctuating course symptoms and a possible spontaneous resolution, have elicited interest among the scientific community. However, many issues are still open on the underlying pathogenesis, clinical, and therapeutic management and long-term outcome. Materials and MethodsWe retrospectively analyzed clinical, radiological and laboratory records of all patients diagnosed with SLS between 2011 and 2021 at 4 National referral centers for Pediatric Onco-Hematology. Patients with a latency period that was longer than 3 weeks between the last MTX administration of MTX and SLS onset were excluded from the analysis, as were those with unclear etiologies. We assessed symptom severity using a dedicated arbitrary scoring system. Eleven patients were included in the study. ResultsThe underlying disease was acute lymphoblastic leukemia type B in 10/11 patients, while fibroblastic osteosarcoma was present in a single subject. The median age at diagnosis was 11 years (range 4-34), and 64% of the patients were women. Symptoms occurred after a mean of 9.45 days (+/- 0.75) since the last MTX administration and lasted between 1 and 96 h. Clinical features included hemiplegia and/or cranial nerves palsy, paraesthesia, movement or speech disorders, and seizure. All patients underwent neuroimaging studies (CT and/or MRI) and EEG. The scoring system revealed an average of 4.9 points (+/- 2.3), with a median of 5 points (maximum 20 points). We detected a linear correlation between the severity of the disease and age in male patients. ConclusionsSLS is a rare, well-characterized complication of MTX administration. Despite the small sample, we have been able to confirm some of the previous findings in literature. We also identified a linear correlation between age and severity of the disease, which could improve the future clinical management
A Study of the Pyrolysis Products of Kraft Lignin
In order to valorize lignin wastes to produce useful aromatic compounds, the thermal degradation pyrolysis of Kraft lignin in the absence of catalysts has been investigated at 350, 450, and 550 °C. The high content of sulfur in the fresh sample led to the formation of S-containing compounds in products whose evolution in the gas phase was monitored through GC-MS analysis. Pyrolytic gas is rich in CH4, CO, CO2, and H2S with the presence of other sulfur compounds in smaller amounts (i.e., CH3SH, CH3-S-CH3, SO2, COS, and CS2). Biochar morphology and elemental composition have been investigated by means of SEM and EDX. The carbon content reaches ~90% after pyrolysis at 550 °C, while the oxygen content showed a decreasing trend with increasing temperature. From GC-MS analysis, bio-oil resulted rich in alkyl-alkoxy phenols, together with (alkyl)dihydroxy benzenes and minor amounts of hydrocarbons and sulfur compounds. NaOH/H2O and EtOH/H2O extraction were performed with the aim of extracting phenolic-like compounds. Sodium hydroxide solution allowed a better but still incomplete extraction of phenolic compounds, leaving a bio-oil richer in sulfur
A Study of the Pyrolysis Products of Kraft Lignin
In order to valorize lignin wastes to produce useful aromatic compounds, the thermal degradation pyrolysis of Kraft lignin in the absence of catalysts has been investigated at 350, 450, and 550 °C. The high content of sulfur in the fresh sample led to the formation of S-containing compounds in products whose evolution in the gas phase was monitored through GC-MS analysis. Pyrolytic gas is rich in CH4, CO, CO2, and H2S with the presence of other sulfur compounds in smaller amounts (i.e., CH3SH, CH3-S-CH3, SO2, COS, and CS2). Biochar morphology and elemental composition have been investigated by means of SEM and EDX. The carbon content reaches ~90% after pyrolysis at 550 °C, while the oxygen content showed a decreasing trend with increasing temperature. From GC-MS analysis, bio-oil resulted rich in alkyl-alkoxy phenols, together with (alkyl)dihydroxy benzenes and minor amounts of hydrocarbons and sulfur compounds. NaOH/H2O and EtOH/H2O extraction were performed with the aim of extracting phenolic-like compounds. Sodium hydroxide solution allowed a better but still incomplete extraction of phenolic compounds, leaving a bio-oil richer in sulfur